Canaan Partners Xi LLC Day One Biopharmaceuticals, Inc. Transaction History

Canaan Partners Xi LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 01, 2024	SELL	$9.68 - $15.37 $24.1 Million - $38.3 Million	-2,491,561 Closed	0 $0
Q3 2023 Oct 11, 2023	SELL	$11.22 - $14.86 $637,767 - $844,672	-56,842 Reduced 2.23%	2,491,561 $30.6 Million
Q4 2022 Feb 01, 2023	SELL	$18.77 - $22.0 $82.9 Million - $97.1 Million	-4,415,898 Reduced 63.41%	2,548,403 $54.8 Million
Q3 2022 Oct 31, 2022	SELL	$16.44 - $26.57 $44.4 Million - $71.7 Million	-2,699,344 Reduced 27.93%	6,964,301 $139 Million
Q4 2021 Feb 03, 2022	BUY	$15.65 - $26.33 $151 Million - $254 Million	9,663,645 New	9,663,645 $163 Million

148

60M

47.7K

61.3K

Ticker DAWN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,461,104
Market Cap $1.09B
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...

Get notified when there are updates to the investment portfolio of Canaan Partners Xi LLC, based on Form 13F filings with the SEC.

Stay updated on Canaan Partners Xi LLC with notifications on news.